cardiovascular disease
Heart and blood-vessel disease: drugs and devices that treat or prevent it.
Theme · 16 companies · 3 report it as a revenue line
ABT Abbott Laboratories
Sells it“9M FX-adjusted growth included Electrophysiology +13.8%, Rhythm Management +10.6%, Heart Failure +8.9%, Vascular +5.2%, Structural Heart +2.6%, Neuromodulation +1.3% and Diabetes Care +7.7%.”
- Revenue$13.0BYoY +14.5%
- Net income$920.0MYoY −44.0%
ADRX ADARx Pharmaceuticals, Inc.
In development“Our Factor XI (FXI) program, ADX-626, is in development for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.”
AMGN Amgen
Sells it 8%, $3.0B a year“Repatha was launched in 2015 and is indicated to reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.”
- Revenue$36.8BYoY +10.0%
- Net income$7.7BYoY +88.5%
- Revenue$10.4BYoY +8.5%
- Net income$3.9BYoY +20.1%
BMY Bristol-Myers Squibb
Sells it 32%, $15.5B a year“Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.”
- Revenue$48.2BYoY −0.2%
- Net income$7.1Bvs −$8.9B year ago
- Revenue$13.1BYoY +6.9%
- Net income$2.2BYoY −1.8%
BRVE Braveheart Bio, Inc.
In development“Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non-obstructive HCM (“nHCM”).”
BSX Boston Scientific
Sells it“Cardiovascular growth benefited from the AGENT drug-coated balloon; Farapulse pulsed-field ablation also supported year-to-date growth.”
- Revenue$5.1BYoY +1.4%
- Net income$582.0MYoY −22.9%
CTY CITY THERAPEUTICS, INC.
In development“We are advancing CITY-FXI for the prevention of thromboembolic diseases based on its potential to reduce FXI activity and thereby prevent thromboembolic events while mitigating bleeding risk.”
EMI Encore Medical, Inc.
Sells it“Septal occlusion devices are small, implantable devices that are positioned and delivered through a catheter inserted into a major blood vessel (typically via femoral venous access) to repair certain cardiac defects in both adults and children.”
JNJ Johnson & Johnson
Sells it“Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration).”
- Revenue$94.2BYoY +6.0%
- Net income$26.8BYoY +90.6%
- Revenue$25.4BYoY +5.9%
- Net income$210.0MYoY −95.9%
LLY Eli Lilly and Company
Sells it“Jardiance In collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults; and to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.”
- Revenue$65.2BYoY +44.7%
- Net income$20.6BYoY +94.9%
- Revenue$24.4BYoY +38.6%
- Net income$6.5BYoY +15.5%
MDT Medtronic
Sells it“Cardiovascular growth was led by pulsed-field ablation, cardiac pacing and defibrillation; ICT also benefited from TAVR and renal denervation products.”
- Revenue$9.8BYoY +13.7%
- Net income$1.5BYoY +41.3%
MRK Merck & Co.
Sells it 3%, $2.2B a year“Winrevair (sotatercept-csrk), an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death;”
- Revenue$65.0BYoY +1.3%
- Net income$18.3BYoY +6.6%
- Revenue$18.1BYoY +4.7%
- Net income$5.1BYoY −12.4%
OURA Oura Inc.
Sells it“Continuous cardiovascular measurements are contextualized against personalized baselines.”
PFE Pfizer
Sells it“Internal medicine product portfolio including in cardiovascular metabolic diseases – select products include: Eliquis, as well as other brands that have experienced patent-based expirations or loss of regulatory exclusivity.”
- Revenue$62.6BYoY −1.6%
- Net income$7.8BYoY −3.2%
- Revenue$16.6BYoY −0.4%
- Net income$3.2BYoY −8.4%
RZRA Rezera Inc.
In development“When NLRP3 becomes chronically activated, it stimulates this cascade of inflammatory mediators that drive the development and progression of cardiovascular and neuroinflammatory disease.”
SCTX Scribe Therapeutics, Inc.
In development“Our focus is on cardiovascular and metabolic, or CVM, diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD.”
No companies have a recent 8-K matching these events.
No companies in the selected roles.